Literature DB >> 6136412

Time course of the bronchial response to salbutamol after placebo, betaxolol and propranolol.

R Palminteri, G Kaik.   

Abstract

The effects on specific airway conductance (sGaw) of placebo, betaxolol and propranolol following the inhalation of salbutamol were studied in 8 healthy volunteers by whole body plethysmography. Each subject received placebo and single oral doses of betaxolol 40 mg and 80 mg, and propranolol 160 mg, and 320 mg. sGaw was measured before dosing and after 2 h, just before salbutamol was inhaled. It was then measured again after 15 min and 0.5, 1, 2, 3, 4 and 6 h. sGaw 2 h after the beta-blockers did not differ from the value whilst on placebo. The peak response to salbutamol after placebo and both doses of betaxolol was almost identical, whereas it was significantly reduced after propranolol. The AUC of the response to salbutamol over 6 h showed a reduction of 11% after betaxolol and of 19% after propranolol (p less than 0.01 between beta-blockers). The results indicate that, after betaxolol and in contrast to propranolol, a proportion of the bronchial beta 2-receptor population remains available to a beta 2-agonist.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6136412     DOI: 10.1007/bf00607080

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  beta-Adrenoceptor antagonists and respiratory function.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

2.  Selectivity of beta-adrenoceptor agonists and antagonists in asthmatics.

Authors:  C G Löfdahl
Journal:  Eur J Respir Dis Suppl       Date:  1982

3.  Assessment of bronchial beta blockade after oral bevantolol.

Authors:  A D Mackay; H R Gribbin; C J Baldwin; A E Tattersfield
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

4.  Identification of different subgroups of beta-receptors by means of binding studies in guinea-pig and human lung.

Authors:  G Engel
Journal:  Triangle       Date:  1980

5.  Assessing change in airway calibre--measurement of airway resistance.

Authors:  A E Tattersfield; I M Keeping
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

6.  beta-adrenergic agonist resistance in normal human airways.

Authors:  S T Holgate; C J Baldwin; A E Tattersfield
Journal:  Lancet       Date:  1977-08-20       Impact factor: 79.321

7.  Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.

Authors:  K Balnave; J D Neill; C J Russell; D W Harron; W J Leahey; R Wilson; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

8.  Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man.

Authors:  J F Giudicelli; M Chauvin; C Thuillez; C Richer; G Bianchetti; R Gomeni; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

9.  Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration.

Authors:  S J Warrington; P Turner; J R Kilborn; G Bianchetti; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

10.  Bronchial and cardiac beta-adrenoceptor blockade--a comparison of atenolol, acebutolol and labetalol.

Authors:  H R Gribbin; A D Mackay; C J Baldwin; A E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

View more
  5 in total

1.  The affinity of betaxolol, a beta 1-adrenoceptor-selective blocking agent, for beta-adrenoceptors in the bovine trachea and heart.

Authors:  E Satoh; A Narimatsu; Y Hosohata; H Tsuchihashi; T Nagatomo
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

Review 2.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 3.  Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  M M Buckley; K L Goa; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 4.  Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension.

Authors:  R Beresford; R C Heel
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

5.  Use of propranolol blockade to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers: results from two randomized trials.

Authors:  Virginia Norris; Claire Ambery
Journal:  Drugs R D       Date:  2014-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.